Form 4: Cidara Therapeutics Executive Leslie Tari Reports Acquisition of Restricted Stock Units and Stock Options

Leslie Tari, Chief Scientific Officer of Cidara Therapeutics, reports the acquisition of restricted stock units and stock options, along with a disposition of common stock.

Summary

• On March 15, 2024, Leslie Tari, the Chief Scientific Officer of Cidara Therapeutics, acquired 111,250 shares of common stock in the form of Restricted Stock Units (RSUs) and disposed of 1,484 shares of common stock.
• Additionally, Tari acquired options to purchase 222,500 shares of common stock at an exercise price of $0.6849.
• The RSUs vest in three equal annual installments starting March 10, 2025, and the stock options vest in 36 equal monthly installments from March 15, 2024.
• Following these transactions, Tari directly owns 369,931 shares of common stock and indirectly owns 1,484 shares through a spouse, as well as options for 222,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs and stock options suggests confidence, but the small disposition of shares tempers the positive outlook.

Positives

• The acquisition of RSUs and stock options by a key executive signals confidence in the company's future performance.

Negatives

• The disposition of 1,484 shares of common stock could be interpreted negatively, although the amount is relatively small.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge executive sentiment and potential future stock performance.

Stakeholder Impact

• The reported transactions may influence investor perception of Cidara Therapeutics and its stock.

Key Dates